Notably, recent evidence showing efficacy of CVD medications such as PCSK9 inhibitors in ameliorating CVD biomarkers such as low-density lipoprotein cholesterol (LDLC) also demonstrated reductions in psychological distress and improved quality of life, indicating a potential pathway for interventions targeting psychosocial stress and CVD [72]. This evidence concerns the gene PCSK9 and Abnormal emotional state.